Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VX-950 · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| VX-950 | DRUG | - |
| ribavirin | DRUG | - |
| peginterferon alfa-2a | DRUG | - |
| peginterferon | DRUG | - |
Inclusion Criteria: * Infected with hepatitis C virus Exclusion Criteria: * Contraindications to peginterferon or ribavirin therapy.
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | - | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | - | Undisclosed |
VX-950 is an investigational small molecule being developed for the treatment of Hepatitis C. It is currently in Phase 2 clinical development and has not been approved by the FDA. The drug is being studied in combination with peginterferon and ribavirin for this infectious disease indication.
VX-950 is being developed by Vertex Pharmaceuticals Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker symbol VRTX. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Hepatitis C.
VX-950 is in Phase 2 clinical development for Hepatitis C. It is an investigational drug, meaning it has not yet received regulatory approval. Two clinical trials have been completed, including a Phase 1 and a Phase 2 study, with a total of 32 participants enrolled.
VX-950 has been studied in two completed clinical trials. NCT00251199 was a Phase 1 study of VX-950 and peginterferon for Hepatitis C with 20 participants in Germany and the Netherlands. NCT00262483 was a Phase 2 study of VX-950, Pegasys and Copegus in Hepatitis C with 12 participants in the United States and Puerto Rico.
VX-950 is the development code for the drug also known as telaprevir. It is a small molecule protease inhibitor being studied for Hepatitis C. The drug has been evaluated in clinical trials in combination with peginterferon and ribavirin, though it remains investigational and is not yet approved.